Susan Clavette
Psychiatric/Mental Health · Overland Park, KSNPI 1770903114
Payments from drug & device makers
Across 588 payments — averaging $15.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$1K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- Lundbeck LLC$1K
- Axsome Therapeutics, Inc.$687
- Supernus Pharmaceuticals, Inc.$649
- AbbVie$530
- plus $4K from 23 others
What the payments were for
- Food & beverage$8,81598%
- Education$2232%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 96 | $1,432 |
| Takeda Pharmaceuticals U.S.A., Inc. | 69 | $1,058 |
| Lundbeck LLC | 75 | $1,010 |
| Axsome Therapeutics, Inc. | 36 | $687 |
| Supernus Pharmaceuticals, Inc. | 39 | $649 |
| AbbVie | 43 | $530 |
| Vanda Pharmaceuticals Inc. | 26 | $435 |
| Almatica Pharma LLC | 29 | $361 |
| Teva Pharmaceuticals USA, Inc. | 12 | $310 |
| Harmony Biosciences LLC | 9 | $288 |
| E.r. Squibb & Sons, L.L.C. | 17 | $272 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 22 | $259 |
| Corium, LLC | 16 | $226 |
| Avanir Pharmaceuticals, Inc. | 18 | $188 |
| Merck | 12 | $159 |
| Neurocrine Biosciences, Inc. | 8 | $153 |
| Collegium Pharmaceutical, Inc. | 11 | $144 |
| Tris Pharma Inc | 6 | $141 |
| Noven Therapeutics, LLC | 8 | $140 |
| Neos Therapeutics, LP | 7 | $119 |
| Eisai Inc. | 6 | $100 |
| Arbor Pharmaceuticals, Inc. | 7 | $94 |
| Azurity Pharmaceuticals, Inc. | 5 | $86 |
| Idorsia Pharmaceuticals US Inc | 4 | $85 |
| Tempus AI, Inc | 2 | $40 |
| Jazz Pharmaceuticals Inc. | 2 | $30 |
| Adlon Therapeutics L.p. | 1 | $15 |
| Johnson & Johnson | 1 | $14 |
| Lilly USA, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NUEDEXTA$125
- REXULTI$124
- Austedo XR$110
- Fanapt$103
How this compares
$9,038 in reported general payments places this provider in the 95th percentile of 404 psychiatric/mental health providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 28 | $43,714 |
| NuedextaDextromethorphan Hbr/Quinidine | 22 | $36,481 |
| FanaptIloperidone | 12 | $32,502 |
| TrintellixVortioxetine Hydrobromide | 11 | $12,354 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 85 | $5,891 |
| VyvanseLisdexamfetamine Dimesylate | 13 | $5,379 |
| Lisdexamfetamine Dimesylate | 18 | $4,617 |
| Methylphenidate ErMethylphenidate Hcl | 15 | $3,208 |
| Vilazodone Hcl | 47 | $2,788 |
| Ziprasidone Hcl | 31 | $2,006 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 60 | $1,891 |
| Oxcarbazepine | 16 | $1,555 |
| Trazodone Hcl | 112 | $1,175 |
| Guanfacine Hcl ErGuanfacine Hcl | 24 | $987 |
| Alprazolam | 166 | $984 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,432 | $43,71428 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $188 | $36,48122 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $435 | $32,50212 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $1,058 | $17,73324 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 404 psychiatric/mental health providers in Kansas.
Other psychiatric/mental health in Overland Park
- Theresa MuellerOverland Park$14K
- Georgette KairangaOverland Park$13K
- Omozuwa OmigieOverland Park$10K
- Laura YoungOverland Park$5K
- Eric ThomasonPittsburg$333K
- Belinda BagbyHutchinson$39K
- Hayley KnappWichita$31K
- Jennifer KubinBaldwin City$26K
- Uyen DinhPittsburg$20K
- Louise MuhoziKansas City$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.